Company
LON:SBTX
SkinBioTherapeutics PLC is a life science company focused on skin health. The company’s proprietary platform technology, SkinBiotix ® , is based upon discoveries made at The University of Manchester.
156 stories · page 7 of 8
The cream has been formulated to contain SkinBioTherapeutics' proprietary technology, SkinBiotix; tests have proved the cream formulation retains the same beneficial properties as the original technology
FTSE 100 closed higher, as did it mid-cap cousin, FTSE 250
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at some of the biggest risers and fallers in London on Tuesday
The company has been speaking to a range of commercial partners interested in evaluating its SkinBiotix technology ahead of its human studies, which are scheduled to commence later this year
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of today's top risers and fallers in London
There is a growing awareness of the SkinBiotix platform technology from the skin healthcare industry
Investments and investor services
The premier UK share index closed up around 24 points at 7,281.
The numbers are not expected to contain too many surprises - which will come as a merciful relief to Lloyds' shareholders - but the bank's strategic review might provide some talking points
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Some of the main biggest risers and fallers in London on Friday
It was another quiet day in London but also another record close
The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells)
SkinBiotix recently passed an independent in-vitro (test tube) cytotoxicity safety test with flying colours
On Tuesday PureTech said affiliate Vedanta Biosciences had in-licensed microbiome-derived cancer immunotherapies based on live biotherapeutics
